Asset Management One Co. Ltd. Purchased 1,248 Shares of DexCom, Inc. (DXCM)

Asset Management One Co. Ltd. Purchased 1,248 Shares of DexCom, Inc. (DXCM)

Asset Management One Co. Ltd. raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.0% during the first quarter, Holdings Channel reports. The institutional investor owned 128,602 shares of the medical device company’s stock after buying an additional 1,248 shares during the period. Asset Management One Co. Ltd.’s holdings in DexCom were worth $10,899,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Accredited Investors Inc. acquired a new position in DexCom during the third quarter worth approximately $207,000. Marble Harbor Investment Counsel LLC raised its stake in shares of DexCom by 7.2% in the third quarter. Marble Harbor Investment Counsel LLC now owns 12,660 shares of the medical device company’s stock worth $1,110,000 after buying an additional 850 shares during the last quarter. March Altus Capital Management LP raised its stake in shares of DexCom by 21.4% in the third quarter. March Altus Capital Management LP now owns 14,200 shares of the medical device company’s stock worth $1,245,000 after buying an additional 2,500 shares during the last quarter. Zevenbergen Capital Investments LLC raised its stake in shares of DexCom by 6.7% in the third quarter. Zevenbergen Capital Investments LLC now owns 533,235 shares of the medical device company’s stock worth $46,743,000 after buying an additional 33,360 shares during the last quarter. Finally, BOKF NA purchased a new stake in shares of DexCom during the third quarter worth about $316,000.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. The business had revenue of $142.30 million during the quarter, compared to the consensus estimate of $143.94 million. DexCom had a negative net margin of 10.64% and a negative return on equity of 23.61%.

A number of analysts recently issued reports on DXCM shares. B. Riley reiterated a “buy” rating and issued a $95.00 price target on shares of DexCom in a report on Thursday, April 27th. Oppenheimer Holdings Inc. set a $98.00 price target on DexCom and gave the company a “buy” rating in a report on Wednesday, March 1st. Canaccord Genuity reiterated a “buy” rating and issued a $95.00 price target on shares of DexCom in a report on Friday, February 10th. Northcoast Research reiterated a “buy” rating on shares of DexCom in a report on Wednesday, March 1st. Finally, BTIG Research lowered DexCom from a “buy” rating to a “neutral” rating in a report on Wednesday, May 3rd. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $90.44.

In other news, Director Jay S. Skyler sold 31,890 shares of DexCom stock in a transaction on Monday, March 6th. The shares were sold at an average price of $78.13, for a total transaction of $2,491,565.70. Following the completion of the sale, the director now directly owns 5,011 shares of the company’s stock, valued at approximately $391,509.43. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Richard Doubleday sold 3,182 shares of DexCom stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $68.29, for a total transaction of $217,298.78. Following the sale, the executive vice president now directly owns 72,395 shares of the company’s stock, valued at $4,943,854.55. The disclosure for this sale can be found here. In the last 90 days, insiders sold 132,202 shares of company stock valued at $10,070,171. Insiders own 2.80% of the company’s stock.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:DXCM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Related posts

Leave a Comment